Brought to you by 
Bayer divests its plasma unit to US investors
26 May 2005
Executive Summary
Bayer AG has agreed to sell the plasma products business of Bayer Biological Products, a division of its US subsidiary Bayer HealthCare, to a newly formed company (initially called NPS BioTherapeutics) controlled by affiliates of the private US investment groups Cerberus Capital Management and Ampersand Ventures. The total consideration is €450mm ($590mm) in cash, a 10% stake in NPS, and potential earn-outs of up to $60mm.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer divests its plasma unit to US investors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice